Skip to main
SRPT
SRPT logo

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 44 analyst ratings
Buy
Strong Buy 20%
Buy 36%
Hold 34%
Sell 5%
Strong Sell 5%

Bulls say

Sarepta Therapeutics Inc. is positioned for significant financial improvement, with the transition to a new manufacturing process set to enhance margins to approximately 90% for its gene therapy programs by 2027. The company's robust commercial execution is anticipated to propel sales, with projections estimating FY 2025 Elevidys sales at around $2.2 billion, reflecting a strong growth trajectory. Furthermore, the successful growth of the Vyondys product in Q4 2024 and the overall revenue expectations paint a positive outlook for the company's financial performance in the coming years.

Bears say

Sarepta Therapeutics faces significant risks that negatively impact its outlook, including the potential for lower-than-expected sales from its commercial products and concerns related to gene therapy safety signals from ongoing trials. The company's focus on rare diseases may lead to delays in patient recruitment, which would adversely affect sales estimates, compounded by flat sales for its Amondys product and a slight decline for Exondys, alongside increasing competition from alternative therapies. Furthermore, the early-stage nature of many of its product candidates, combined with potential regulatory hurdles, casts uncertainty over the company's ability to achieve its projected market potential.

Sarepta Therapeutics (SRPT) has been analyzed by 44 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 36% recommend Buy, 34% suggest Holding, 5% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Buy based on their latest research and market trends.

According to 44 analysts, Sarepta Therapeutics (SRPT) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.